info@biomedres.us
+1 (502) 904-2126
One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA
Site Map
ISSN: 2574 -1241
ISSN: 2574 -1241
Received: February 21, 2018; Published: March 01, 2018
DOI: 10.26717/BJSTR.2018.02.000814
Inhibition of angiogenesis, which refers to blocking the vessel formation from pre-existing blood vessels, has become an attractive target for cancer therapy. Tumors beyond 2-3 mm in size induce the sprouting of new blood vessels from the surrounding vasculature (sprouting angiogenesis). Design and development of new angiogenesis inhibitors has been validated as a target in several tumor types. In this min-review, we will focus on the role of different anti-angiogenesis strategies and inhibitors in treatment of cancer.
Keywords: VEGF: Vascular Endothelial Growth Factor; TGF: Transforming Growth Factor; TNF: Tumor Necrosis Factor; bFGF: Basic Fibroblast Growth Factor; PLGA: Poly Lactic-Co-Glycolic Acid
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China
Full Text
PDF
